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Abstract
IMPORTANCE The association of rheumatoid arthritis (RA) with cognitive and psychiatric
phenotypes has been recognized. However, it is not knownwhether these phenotypes are a
consequence of disease-related factors, such as pain, or reflect shared etiological factors.
OBJECTIVE To investigate whether genomic risk for RA is associated with cognitive and psychiatric
symptoms in children and adolescents.
DESIGN, SETTING, AND PARTICIPANTS This cohort study analyzed data from 3296 to 5936
adolescents (depending on outcome) from the Avon Longitudinal Study of Parents and Children.
Clinical and questionnaire data were collected periodically from September 6, 1990, with collection
ongoing, and analyzed from August 21, 2017, to May 21, 2018.
EXPOSURES Polygenic risk scores (PRSs) for RA.
MAINOUTCOMES ANDMEASURES Measures of cognition (including IQ, workingmemory, verbal
learning, processing speed, problem solving, selective attention, and attentional control) and
psychopathology (including anxiety, depression, negative symptoms, psychotic experiences,
attention-deficit/hyperactivity disorder, and hyperactive and inattentive symptoms) in childhood
and adolescence.
RESULTS Polygenic risk scores for RAwere generated for 7977 children and adolescents (3885
[48.7%] female). Of these 7977 participants, 9 (0.11%) had a known diagnosis of RA at age 22 years.
Increased PRS for RAwas associated with lower total IQ (β, −0.05; 95%CI, −0.07 to −0.02; P < .001),
performance IQ (β, −0.03; 95% CI, −0.06 to −0.005; P = .02), and verbal IQ (β, −0.05; 95% CI,
−0.08 to −0.02; P < .001) at age 8 years (mean [SD] age at measurement, 8.6 [0.3] years) and
symptoms of hyperactivity and inattention from ages 4 to 16 years, with the strongest evidence of
association at age 13 years (mean [SD] age at assessment, 13.2 [0.2] years). The odds ratio at this age
per SD increase in PRSwas 1.25 (95%CI, 1.12-1.39) (P < .001). Therewas little evidence of association
between the RA PRS and other measures of cognition and psychopathology. Gene-based analyses
indicated that polygenic signal for RA was enriched for immune pathways (q  0.05). No equivalent
associations were seen for polygenic risk associated with inflammatory bowel disease or multiple
sclerosis.
CONCLUSIONS ANDRELEVANCE These findings support an association between genetic risk for
RA and neural phenotypes, suggesting that cognitive impairment in RA is not simply secondary to
disease-related processes or treatment effects. These results may suggest that genetic susceptibility
for RAmight affect psychological well-being in early life and reinforce the emerging link between
mental health and the immune system.
JAMA Network Open. 2019;2(6):e196118. doi:10.1001/jamanetworkopen.2019.6118
Key Points
Question Is genetic liability for
rheumatoid arthritis associated with
cognitive and psychiatric phenotypes in
children prior to the clinical onset
of disease?
Findings In this cohort study of 7977
children and adolescents, genetic
liability for rheumatoid arthritis was
associated with lower total,
performance, and verbal IQ at age 8
years and symptoms of hyperactivity
and inattention from ages 4 to 16 years.
However, there was little evidence of
association with other domains of
psychopathology.
Meaning These findings support a
primary etiological association between
genetic risk for rheumatoid arthritis and
cognitive phenotypes that is not simply
secondary to disease-related processes
or reverse causation.
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Introduction
Rheumatoid arthritis (RA) is a highly heritable chronic inflammatory disease that affects between
0.5% and 1% of the population and is most common in older adults.1 It has long been recognized that
there are elevated rates of cognitive and psychiatric phenotypes in patients with RA.2,3 For example,
a number of studies4,5 have reported evidence of specific areas of cognitive difficulty in adults with
RA, including poorer performance in tests of verbal IQ, attention, andmemory.4 Patients with RA are
also reported to have increased rates of a number of psychiatric conditions.6 Rates of depression in
individuals with RA are elevated to 2 to 4 times the levels seen in the general population.2,3,7 Similarly
increased rates of anxiety disorders are also reported.2 While mental disorders such as depression
and anxiety are more common in individuals with RA, the association between RA and psychotic
disorders such as schizophrenia is more complex. Epidemiological studies have shown decreased
rates of RA in those with schizophrenia.8 However, this has not been a universal finding, and
uncertainty remains about whether there are altered rates of psychotic disorders in people with RA.9
There is also evidence that the offspring ofmothers with RA aremore likely to suffer from attention-
deficit/hyperactivity disorder (ADHD), although it is not knownwhether this reflects shared genetic
vulnerability across the disorders or exposure to the heightened inflammatory status (or associated
medication) in themother.10
Despite the robust evidence of cognitive deficits and increased presence of some psychiatric
disorders in people with RA, themechanism underlying these associations is unknown. Rheumatoid
arthritis is not typically considered a disorder of the brain, butmultiple disease-related factors could
potentially affect central nervous system (CNS) function. These include the effects of RA symptoms
such as pain; treatmentwith disease-modifying antirheumatic or biological drugs known to have CNS
effects; the impact of heightened systemic inflammation on the brain; indirect effects of RA
symptoms, such as decreased activity levels or social isolation; and a direct effect of shared risk
factors for RA on brain function. The latter possibility is particularly intriguing given the increasing
evidence that the immune system plays a direct role in nervous system development and
function.11-13 Delineating the significance of each of these associations in patients with active disease
is difficult owing to their health status and clinical management. However, general population studies
examining the effects of risk factors for RA provide an opportunity to study alternative explanations
for these associations while excluding RA disease-relatedmechanisms.
Recent large-scale meta-analyses of genome-wide association studies (GWAS) of RA have
shown that there is a significant association of common genetic variants with disease risk.14 Using
these data, we have used a polygenic risk score (PRS) approach15-17 to examine whether genetic
liability for RA is associated with cognitive and psychiatric phenotypes in children and adolescents
prior to the clinical onset of autoimmune disease and disease-related factors. To investigate the
selectivity of our results to RAwe also compared results with those obtained from associations
between PRSs for 2 additional inflammatory disorders, inflammatory bowel disease (IBD) and
multiple sclerosis (MS).
Methods
Study Population
The sample comprised young individuals within the Avon Longitudinal Study of Parents and Children
(ALSPAC) longitudinal birth cohort (eMethods in the Supplement).18,19 The ALSPAC children have
had detailed longitudinal assessments of health since birth, and details of all available data can be
found through a fully searchable data dictionary and variable search tool.20 All ALSPAC study
participants who complete questionnaires consent to the use of their data by approved researchers.
Until age 18 years, an overarching parental consentwas used to indicate parents consented for their
child (the study participant) to take part in ALSPAC. Consent for data collection and use, implied via
thewritten completion of questionnaires and parental consent, as well as assent from the child, was
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required for all physical measures and tissue sampling. Study participants have the right to withdraw
their consent for specific elements of the study, or from the study as a whole, at any time. Ethical
approval for the study was obtained from the ALSPAC Ethics and Law Committee and the local
research ethics committees.
Polygenic Risk Scores for Inflammatory Disorders
Genetic data were available for 7977 ALSPAC participants (eMethods in the Supplement). Polygenic
risk scores were constructed using summary statistics from large GWASs for RA,14 IBD,21 and MS.22
The RA discovery sample contained 14 361 cases of RA and 43 923 controls, the IBD discovery sample
contained 12 882 cases of Crohn disease or ulcerative colitis and 21 770 controls, and theMS
discovery sample contained 9772 cases of MS and 17 376 controls. For all inflammatory disorders,
single-nucleotide polymorphism (SNP) association data were taken from the GWAS limited to
individuals of European decent.
Weighted PRSswere calculated for each ALSPAC individual using the PLINK genome association
analysis software version 1.07 “score” command. Our primary analysis included PRSs generated using
SNPs with an inflammatory disorder discovery sample association of P  .05. Polygenic risk scores
based on a range of GWAS P value thresholds (P  .50 to P  1 × 10−7) were also generated and used
in sensitivity analyses.
Owing to the substantial association between loci within themajor histocompatibility complex
(MHC) and inflammatory disorder risk, 2 versions of the PRSs were generated: 1 that included only
a single SNP to represent the extendedMHC region (chromosome 6: 25-34Mb) and 1 that omitted all
SNPs from the extendedMHC region (eMethods in the Supplement).
CognitiveMeasures
Cognitive testing was carried out during a clinic visit of ALSPAC children at age 8 years using a short
form of the Wechsler Intelligence Scale for Children, third edition23 and Test of Everyday Attention
for Children.24 Measures captured using the Wechsler Intelligence Scale for Children included total
IQ, performance IQ, verbal IQ, working memory, verbal learning, processing speed, and problem
solving. Measures captured using the Test of Everyday Attention for Children included selective
attention and attentional control. An additional measure of IQ was also captured at age 15 years
during a clinic visit using theWechsler Abbreviated Scale of Intelligence.25 All cognitive measures
were standardized to have amean of 0 and a standard deviation of 1 before analysis. The eMethods
in the Supplement include additional details on all measures.
PsychiatricMeasures
Measures of psychopathology were taken at multiple ages (ranging from 4 to 18 years). Measures
include presence of anxiety (at age 18 years), depression (at age 18 years) (bothmeasured using the
Clinical Interview Schedule-Revised26), negative symptoms (at age 16 years; measured using the
Community Assessment of Psychic Experiences self-report questionnaire27), psychotic experiences
(at ages 12 and 18 years; measured using the semistructured Psychosis-Like Symptom
Interview28,29), ADHD (at age 7 years; measured using the Development andWell Being
Assessment30), and hyperactive and inattentive symptoms (at ages 4, 7, 8, 10, 12, 13, and 16 years;
measured using the parent-rated 5-item Strengths and Difficulties Questionnaire31).
InflammatoryMarkers
The proinflammatory cytokine interleukin 6 and the acute-phase protein C-reactive protein were
measured using nonfasting blood samples collected in ALSPAC participants at age 9 years using
methods described previously.32 C-reactive protein was also measured using fasting blood samples
collected in ALSPAC participants at age 16 years usingmethods described previously.33 Inflammatory
marker measures were log transformed before use.
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Gene-BasedAnalyses
To investigate themolecular pathways associated with genetic risk for RA, and to determine whether
any of these contribute to the observed associations with cognitive and psychiatric phenotypes,
gene-based statistics were derived using results of the RA GWAS14 using Multi-marker Analysis of
GenoMic Annotation,34 which was also used to test whether RA genes were enriched in 7321 gene-
ontology gene sets (excluding genes within the extended MHC region) (eMethods in the
Supplement).
For gene sets surviving multiple testing correction, hierarchical clustering analysis was used to
identify gene sets that were correlated based on shared gene overlap as implemented in the package
“stats” in R statistical software version 3.3.1 (R Project for Statistical Computing). Results of the
hierarchical clustering analysis were plotted in as a dendrogram format and broader cluster
definitions were derived via manual inspection (eFigure 1 in the Supplement). Polygenic risk scores
for RA based on SNPs within each gene set cluster were then derived using the methods previously
mentioned.
Statistical Analysis
Univariate linear regression was used to test associations between inflammatory disorder PRSs and
continuous measures, including all cognitive measures and inflammatory markers. Univariate logistic
regression was used to test associations between inflammatory disorder PRSs and dichotomous
measures, including presence of anxiety, depression, negative symptoms, psychotic experiences,
ADHD, and hyperactive and inattentive symptoms. Results of linear regression analyses are
presented as β coefficients (standardized unit changes in the dependent variable per standardized
unit change in the inflammatory disorder PRS) and results of logistic regression analyses are
presented as odds ratios (odds that the dependent variable will occur per standardized unit change
in the inflammatory disorder PRS). A 2-tailed P value less than .05 was considered statistically
significant. However, effect sizes and confidence intervals are presented to allow readers to gauge
the range of values compatible with the true value in the population. All statistical analyses were
performed in Stata statistical software version 15.1 (StataCorp LLC).
Results
Polygenic risk scores for RA, IBD, andMSwere derived for 7977 participants (3885 [48.7%] female)
from the ALSPAC longitudinal birth cohort. Mean ages, analysis sample sizes, and descriptive
statistics for each outcome are shown in eTables 1, 2, and 3 in the Supplement. Of the 7977
participants with PRS data, 9 (0.11%; 7 female and 2male) had a known diagnosis of RA, 23 (0.29%;
15 female and 8male) had a known diagnosis of IBD, and 1 (0.01%; female) had a known diagnosis of
MS at age 22 years.
Associations Between Polygenic Risk for RA and Cognitive Phenotypes
At age 8 years (mean [SD] age at measurement, 8.6 [0.3] years), the RA PRS was associated with a
lower total IQ (β, −0.05; 95% CI, −0.07 to −0.02; P < .001; R2 = 0.002) (Figure 1; eTable 4 in the
Supplement). Particularly strong findings were observed for verbal IQ (β, −0.05; 95% CI, −0.08 to
−0.02; P < .001; R2 = 0.003) (Figure 1; eTable 4 in the Supplement), while evidence was weaker for
performance IQ (β, −0.03; 95% CI, −0.06 to −0.005; P = .02; R2 = 0.001) (Figure 1; eTable 4 in the
Supplement). There was little evidence of association between the RA PRS and other cognitive
measures as collected by ALSPAC (Figure 1; eTable 4 in the Supplement).
To investigate the selectivity of our results to RAwe further investigated associations between
IBD andMS PRSs and measures of IQ and cognition (Figure 1). In contrast to the RA PRS, there was
little evidence of association between the IBD or MS PRSs and IQ (Figure 1; eTable 4 in the
Supplement).
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Associations Between Polygenic Risk for RA and Psychiatric Phenotypes
Polygenic risk scores for RAwere associated with increased odds of hyperactive and inattentive
symptomsmeasured between approximate ages of 4 and 16 years. The strongest evidence of
association was at age 13 years (mean [SD] age at assessment, 13.2 [0.2] years) (odds ratio, 1.25; 95%
CI, 1.12-1.39; P < .001; pseudo R2 = 0.007) (Figure 2; eTable 5 in the Supplement).
There was little consistent evidence of association between RA, IBD, or MS PRSs and anxiety or
depression at age 18 years, negative symptoms at age 16 years, psychotic experiences at age 12 or
18 years, or Development andWell Being Assessment bands predicting a 15% or greater probability
of clinical diagnosis of ADHD at age 7 years (eFigure 2 and eTable 5 in the Supplement).
Associations Between Polygenic Risk for RA and InflammatoryMarkers
There was no association between RA PRSs and plasma interleukin 6 (β, 0.004; 95% CI, −0.03 to
0.03; P = .81; R2 < 0.001) or plasma C-reactive protein (β, 0.001; 95% CI, −0.03 to 0.03; P = .96;
R2 < 0.001) at age 9 years (mean [SD] age at measurement, 9.9 [0.3] years). There was also no
association between RA PRSs and plasma C-reactive protein at age 16 years (mean [SD] age at
measurement, 15.5 [0.4] years) (β, 0.01; 95% CI, −0.03 to 0.04; P = .74; R2 < 0.001) or between IBD
or MS PRSs and any inflammatory marker (Figure 3; eTable 6 in the Supplement).
Figure 1. Associations Between Polygenic Risk Scores (PRSs) for Rheumatoid Arthritis (RA),
Inflammatory Bowel Disease (IBD), andMultiple Sclerosis (MS) and CognitiveMeasures at Age 8 Years
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generated using lists of single-nucleotide
polymorphismsmeeting a P value threshold of .05.
The horizontal black line indicates the null value. The
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Numerical results used to generate the figure are
presented in eTable 4 in the Supplement.
Figure 2. Associations Between Polygenic Risk Scores (PRSs) for Rheumatoid Arthritis (RA),
Inflammatory Bowel Disease (IBD), andMultiple Sclerosis (MS) and Hyperactive and Inattentive Symptoms
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indicating 95% confidence intervals. Odds ratios are
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Numerical results used to generate the figure are
presented in eTable 5 in the Supplement.
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Gene-BasedAnalyses of RA SNPs
After correcting for multiple testing, 106 gene sets were associated with RA (q  0.05), extending
the previously reported pathway analysis of this GWAS.14 Using the proportion of genes overlapping
each of the 106 gene sets and their biological descriptions, we derived 2 gene set clusters
representing biological similarity of individually significant gene sets and 9 gene set subclusters. The
subclusters of gene set cluster 1 were defined as lymphocyte activation and lymphocyte
differentiation. The subclusters of gene set cluster 2 were defined as activated lymphocyte homing,
lymphocyte effector functions, immune activation, Th2 effector characteristics, Th1 and Th17
effector characteristics, lymphokine activities, and immune effector functions (eFigure 1 in the
Supplement).
Polygenic risk scores for RA based on SNPs within each gene set subcluster and SNPs within
clusters 1 and 2, separately and combined, showed little evidence of associationwith IQ at age 8 years
or hyperactive and inattentive symptoms at age 13 years (eFigure 3, eFigure 4, eTable 7, and eTable 8
in the Supplement).
Sensitivity Analyses
The evidence of association between RA PRSs and IQmeasures at age 8 years and hyperactive and
inattentive symptoms was similar when using PRSs omitting all SNPs from the extendedMHC region
and after excluding the 9 individuals who reported an RA diagnosis at age 22 years and individuals
whosemothers had been told by a doctor that they have arthritis (eFigure 5, eFigure 6, eTable 9, and
eTable 10 in the Supplement). Results were also similar when using RA PRSs based on P value
thresholds ranging from less than or equal to .50 to less than or equal to 1 × 10−3 for IQ (eFigure 7 and
eTable 11 in the Supplement) and P value thresholds ranging from less than or equal to .50 to less
than or equal to .01 for hyperactive and inattentive symptoms (eFigure 8 and eTable 12 in the
Supplement). An association between RA PRSs and IQ (β, −0.04; 95% CI, −0.07 to −0.01; P = .02;
R2 = 0.001; N = 3961), but not between IBD PRSs and IQ (β, −0.01; 95% CI, −0.04 to 0.03; P = .71;
R2 < 0.0001; N = 3961) or MS PRSs and IQ (β, −0.02; 95% CI, −0.05 to 0.01; P = .28; R2 = 0.0003;
N = 3961), was also evident at age 15 years.
Discussion
In this study, we have shown that within a general population development cohort, polygenic risk for
RA was associated with measures of IQ at age 8 years and hyperactivity and inattentive symptoms
(most strongly at age 13 years). This supports a primary etiological association between genetic risk
for RA and neural phenotypes that is not simply secondary to disease-related processes or reverse
causation.
Figure 3. Associations Between Polygenic Risk Scores (PRSs) for Rheumatoid Arthritis (RA),
Inflammatory Bowel Disease (IBD), andMultiple Sclerosis (MS) and InflammatoryMarkers
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We found an association between polygenic risk for RA and IQ, with stronger evidence of
association between RA PRS and verbal IQ as compared with performance IQ. This finding is notable
because studies in patient groups have shown that verbal function is one of the most robustly
affected areas of cognition in RA.4 Previous studies have also suggested an association between RA
risk and later cognitive impairment and dementia.35,36 The present results suggest that some of this
vulnerability may be mediated through the effects of genetic risk for RA on cognitive function and
may not solely be caused by disease-related effects or medication.
We also found that the RA PRSwas associated with increased scores onmeasures of inattention
and hyperactivity during childhood. This association was particularly clear across developmental
points associated with the presentation of ADHD. Our results are consistent with a recent large
population study that showed an increased incidence of ADHD inmothers with RA.10 The present
findings suggest that this associationmay result from shared genetic risk factors, rather than from
other factors such as the effects of disease-related inflammation during fetal development, as the
mothers of children in the current study did not predominantly report having RA or related disorders,
and our results remained robust even after excluding those who did report such symptoms. Our
results are also broadly in keeping with the finding that attention is a domain of cognition particularly
affected in patients with RA,4 although the current findings suggest a particularly strong association
of genetic risk for RA with attention during childhood development.
We observed little evidence of association between RA PRS and depression or anxiety-related
phenotypes in this developmental cohort, even though these symptom domains have been
previously associated with RA. This may reflect prior evidence that these phenotypes are particularly
influenced by disease-associated and social factors (including disease severity, pain, and lower
socioeconomic status).3 In fact, while rates of depression are high in patients with RA, they are typical
of the levels seen in a range of chronic diseases.2,37 It is also possible that PRS for RAmay be
associated with risk for these traits, but at a later developmental point as phenotypes such as
depressionmost often emerge in later adolescent and adult life.We also did not detect an association
between RA PRS and psychotic symptoms in these younger individuals, unlike some previous studies
reporting a small overlap between genetic risk for RA and schizophrenia,38 although results from
prior studies have not been consistent.39,40
Our pathway analysis confirms that, even after excluding MHC loci, PRS for RAwas associated
with effects on immune pathways. The finding that RA PRSs were associated with cognitive and
psychiatric phenotypes therefore supports the emerging view that immune pathways play an
important role in brain development and function.11,13 Furthermore, in our healthy population, the
associations were seen in the absence of inflammatory disease or elevated peripheral immune
markers, suggesting a direct CNS effect. Notably, recent studies have begun to demonstrate direct
effects of specific immune pathways, including the complement system and T-cell activation, in
neurodevelopment and behavioral phenotypes.12,41 An important future direction will, therefore, be
to dissect the specific contribution of components of the immune system to nervous system
function.
In contrast to the RA findings, we found little evidence of association between the IBD or MS
PRSs and cognitive or psychiatric symptoms in childhood and adolescence. Previous studies have
suggested increased rates of depression in IBD.42,43 However, akin to RA, these rates are in line with
those seen in chronic diseases more generally. Although there is currently little evidence of specific
cognitive impairments associatedwith IBD, cognitive impairments inMS are well documented.44 Our
findings suggest that the latter potentially occur secondary to illness onset rather than occurring as
earlier (premorbid) changes as observed for RA. However, theMSGWAS had the smallest sample size
of all inflammatory disorders and, therefore, analyses using theMS PRSsmay be underpowered
compared with those for IBD and RA, whose PRSs were based on GWAS samples of similar, and
larger, magnitude. It is also important to note that the IBD GWAS analyses combine data both from
patients with ulcerative colitis and Crohn disease. While these diseases are clearly closely related, it is
possible that future studies may identify a stronger association of genetic risk for one of these
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conditions alonewith neuropsychiatric phenotypes. Overall, the lack of association between PRSs for
IBD or MS and cognitive and psychiatric outcomes in the current study suggests a specific effect of
pathways associated with genetic risk for RA on the CNS.
Strengths and Limitations
A strength of our study is that we used a large, well-characterized longitudinal cohort, albeit of
mostly European ancestry, withmultiple self-report– and interview-basedmeasures on cognition and
psychopathology collected prospectively. However, despite the size of our study, power may have
limited our ability to observe associations with uncommon outcomes. This could explain why we
observed evidence of an association between RA genetic risk and attention and hyperactivity but did
not find an association with syndromal ADHD (based on the top 2 Development andWell Being
Assessment bands,45 estimated prevalence of ADHD at age 7 years was 2.53%). Further analyses in
larger sample sizes are needed to investigate whether genetic liability for RA is associatedwith ADHD
as well as subclinical difficulties.
We also cannot account for potential parental RA effects on child outcomes that are not
mediated through the child’s genetic risk but that are mediated, for example, through effects on the
child’s upbringing. However, excluding individuals whose mothers reported an arthritis diagnosis
had little effect on the results, and while we did not have data on paternal RA, such an explanation
seems unlikely given themean age at onset of RA46 and the ages of child phenotypes studied.
As with most longitudinal cohorts, attrition in ALSPAC leads to underrepresentation of lower
social classes.28 Genetic liability for multiple lifestyle factors, personal characteristics, and health
conditions has also been shown to influence participation in ALSPAC.47 Therefore, our estimates for
IQ and attention and hyperactivity might be affected by selection bias, although one might expect
such a bias to affect all the cognitive and psychiatric phenotypes investigated within this study to a
similar degree.
Conclusions
The associations observed within the current study have implications in terms of the clinical
assessment andmanagement of RA. Overall, RA is currently conceptualized as a multisystem
connective tissue disorder. The current results, however, suggest that CNS impacts should also be
considered a core and primary component of RA, especially in the domain of cognition. Furthermore,
they support the view that clinically it is important to assess andmonitor cognitive impairment in
patients with RA, especially as cognitive factors can affect activities of daily living and individuals’
overall level of functioning.4 Further studies of the role of immune pathways in regulating cognitive
functionmay also lead to the development of new therapeutic approaches for cognitive impairments
in RA and, more broadly, for areas such as ADHD.
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